Enhancement of antitumor effect of cyclophosphamide by thaliblastine in Lewis lung carcinoma and L1210 leukemia in mice.
Cyclophosphamide (CY) was tested in combination with the thalictrum alkaloid named thaliblastine (TBL) for therapeutic activity against early Lewis lung carcinoma and early L1210 leukemia in mice. TBL alone had no activity whereas therapy with CY and TBL was significantly better than with CY alone. The therapeutic potentiation resulting from the combination of CY and TBL is apparently due to the different mechanisms of action and the pharmacological behavior of the two agents.
D000818:Animals; D001060:Aporphines / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004341:Drug Evaluation; D004357:Drug Synergism; D007939:Leukemia L1210 / Q000188:drug therapy*; D008175:Lung Neoplasms / Q000188:drug therapy*; D051379:Mice; D008810:Mice, Inbred C57BL / Q000502:physiology; D008811:Mice, Inbred DBA / Q000502:physiology; D009374:Neoplasms, Experimental / Q000188:drug therapy
D001060:Aporphines; D003520:Cyclophosphamide